Thirty Years of Monoclonal Antibodies: A Long Way to Pharmaceutical and Commercial Success

Antibody–drug conjugates: the success of failure

“…To complete the picture, therapeutic monoclonal antibodies also failed to make a significant medical impact when they were first developed in the 1970s [5]. Their advent gave rise to various new tools in biomedical research and created an expectation that antibodies would provide an immediate and major breakthrough in the treatment of cancer, but then a number of drawbacks were identified and confidence was shaken.…”